| Assessment Status | Rapid Review Complete |
| HTA ID | 23014 |
| Drug | Olipudase alfa |
| Brand | Xenpozyme® |
| Indication | As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B. |
| Assessment Process | |
| Rapid review commissioned | 08/03/2023 |
| Rapid review completed | 31/03/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olipudase alfa compared with the current standard of care. |
| Full HTA commissioned by the HSE | 25/04/2023 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.